Metabolic and Clinical Consequences of Hyperthyroidism on Bone Density
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
In 1891, Von Recklinghausen first established the association between the development of osteoporosis in the presence of overt hyperthyroidism. Subsequent reports have demonstrated that BMD loss is common in frank hyperthyroidism, and, to a lesser extent, in subclinical presentations. With the introduction of antithyroid medication in the 1940s to control biochemical hyperthyroidism, the accompanying bone disease became less clinically apparent as hyperthyroidism was more successfully treated medically. Consequently, the impact of the above normal thyroid hormones in the pathogenesis of osteoporosis may be presently underrecognized due to the widespread effective treatments. This review aims to present the current knowledge of the consequences of hyperthyroidism on bone metabolism. The vast number of recent papers touching on this topic highlights the recognized impact of this common medical condition on bone health. Our focus in this review was to search for answers to the following questions. What is the mechanisms of action of thyroid hormones on bone metabolism? What are the clinical consequences of hyperthyroidism on BMD and fracture risk? What differences are there between men and women with thyroid disease and how does menopause change the clinical outcomes? Lastly, we report how different treatments for hyperthyroidism benefit thyroid hormone-induced osteoporosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk Factors for Hip Fracture in White Women
Cummings, S. R., Nevitt, M. C., Browner, W. S., Stone, K., Fox, K. M., Ensrud, K. E., Cauley, J., Black, D., & Vogt, T. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503233321202 · Cited by 3,595
Bianco, A. C., Salvatore, D., Gereben, B., Berry, M. J., & Larsen, P. R. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.1.0455 · Cited by 1,853
Cellular and molecular mechanisms of bone remodeling
Raggatt, L. J., & Partridge, N. C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.r109.041087 · Cited by 1,402 · cited 1×
“Support for these finding was reported in a more recent cross-sectional study (𝑛 = 6722), which estimated a 31% higher fracture risk (forearm, hip, and vertebral) in patients with TSH <0.10mU/L compared to TSH 1.0–1.49mU/L [44].”
ResultInfluentialCooper, D. S., & Biondi, B. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60276-6 · Cited by 1,039 · cited 3×
“Serum TSH levels may spontaneously return to normal, as can be seen in patients with subclinical hyperthyroidism caused by Graves’ disease or may progress to overt hyperthyroidism, more commonly in patients with autonomous thyroid nodules or multinodular goiters [75].”
BackgroundResultInfluentialTSH Is a Negative Regulator of Skeletal Remodeling
Abe, E., Marians, R. C., Yu, W., Wu, X.-B., Ando, T., Li, Y., Iqbal, J., Eldeiry, L., Rajendren, G., Blair, H. C., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00771-2 · Cited by 691
Fade, J. V., Franklyn, J. A., Cross, K. W., Jones, S. C., & Sheppard, M. C. (1991) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1991.tb01739.x · Cited by 567 · cited 2×
“An estimated 3% of women over the age of 60 are taking exogenous T4 (thyroxine) for medically indicated purposes, either for TSH suppression or as replacement of iatrogenic or endogenous hypothyroidism [96].”
BackgroundRisk for fracture in women with low serum levels of thyroid-stimulating hormone
Bauer, D. C., Ettinger, B., Nevitt, M. C., Stone, K. L., & for the Study of Osteoporotic Fractures Research Group (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-7-200104030-00009 · Cited by 467 · cited 4×
“The same report also found that a history of hyperthyroidism (regardless of duration or degree), after adjustment for TSH concentration and BMD, remains an independent risk factor for hip fracture [52].”
BackgroundInfluentialEffects of thyroid hormones on bone and mineral metabolism
Mosekilde, L., Eriksen, E. F., & Charles, P. (1990) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30338-4 · Cited by 423 · cited 2×
“The accelerated bone remodeling cycle in hyperthyroid states results in increased bone resorption and a subsequent increased release of calcium into systemic circulation [26, 27].”
BackgroundFlynn, R. W., Bonellie, S. R., Jung, R. T., MacDonald, T. M., Morris, A. D., & Leese, G. P. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1625 · Cited by 415
Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis
Uzzan, B., Campos, J., Cucherat, M., Nony, P., Boissel, J. P., & Perret, G. Y. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.12.8954028 · Cited by 398 · cited 2×
“[105] demonstrated similar loss values in their meta-analysis, with BMD losses of 7% of the spine, 5% of the femoral neck, 9% of the trochanter and Ward’s triangle, and 7% of the distal radius.”
ResultFaber, J., & Galløe, A. M. (1994) · European Journal of Endocrinology · doi:10.1530/eje.0.1300350 · Cited by 377
The molecular actions of thyroid hormone in bone
Duncan Bassett, J. H., & Williams, G. R. (2003) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(03)00144-9 · Cited by 261 · cited 1×
“A third deiodinase enzyme, D3, converts T3 and T4 into inactive hormone metabolites reverse T4 (rT2) and rT3 [2].”
BackgroundSubclinical hyperthyroidism: clinical features and treatment options
Biondi, B., Palmieri, E. A., Klain, M., Schlumberger, M., Filetti, S., & Lombardi, G. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01809 · Cited by 217 · cited 1×
“It is unclear if such studies have been able to remove the bias of age, as postmenopausal women may just have had longer durations of low TSH [13, 14, 76, 78–84].”
BackgroundVadiveloo, T., Donnan, P. T., Cochrane, L., & Leese, G. P. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2693 · Cited by 186
Replacement Dosage of L-Thyroxine in Hypothyroidism: A Re-Evaluation
Stock, J. M., Surks, M. I., & Oppenheimer, J. H. (1974) · New England Journal of Medicine · doi:10.1056/nejm197403072901001 · Cited by 184
Trabecular bone remodeling and bone balance in hyperthyroidism
Eriksen, E. F., Mosekilde, L., & Melsen, F. (1985) · Bone · doi:10.1016/8756-3282(85)90218-2 · Cited by 172 · cited 1×
“6% loss of mineralized bone with each cycle in the hyperthyroid group [24].”
BackgroundFöldes, J., Tarján, G., Szathmari, M., Varga, F., Krasznai, I., & Horvath, C. (1993) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1993.tb02403.x · Cited by 170
Thyroid Hormone Use and Bone Mineral Density in Elderly Women: Effects of Estrogen
Schneider, D. L. (1994) · JAMA · doi:10.1001/jama.271.16.1245 · Cited by 157
Faber, Jensen, Petersen, Nygaard, Hegedüs, & Siersbæk‐Nielsen (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00427.x · Cited by 156 · cited 2×
“These results were significant when compared to the untreated controls, inwhomBMDdecreased by about 2% per year at the hip and the spine [93].”
BackgroundResultThe skeletal consequences of thyrotoxicosis
Nicholls, J. J., Brassill, M. J., Williams, G. R., & Bassett, J. H. D. (2012) · Journal of Endocrinology · doi:10.1530/joe-12-0059 · Cited by 138
Bone metabolism during anti‐thyroid drug treatment of endogenous subclinical hyperthyroidism
Mudde, A. H., Houben, A. J. H. M., & Kruseman, A. C. N. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02571.x · Cited by 135
O’Shea, P. J., Harvey, C. B., Suzuki, H., Kaneshige, M., Kaneshige, K., Cheng, S.-Y., & Williams, G. R. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0296 · Cited by 131
Morris, M. S. (2007) · Bone · doi:10.1016/j.bone.2006.12.001 · Cited by 129 · cited 1×
“6mU/L), a statistically significant increase was observed in BMD [48].”
BackgroundGrimnes, G., Emaus, N., Joakimsen, R. M., Figenschau, Y., & Jorde, R. (2008) · Thyroid · doi:10.1089/thy.2008.0158 · Cited by 127
O’Shea, P. J., Bassett, J. H. D., Sriskantharajah, S., Ying, H., Cheng, S.-Y., & Williams, G. R. (2005) · Molecular Endocrinology · doi:10.1210/me.2005-0224 · Cited by 126
Thyroid Status during Skeletal Development Determines Adult Bone Structure and Mineralization
Bassett, J. H. D., Nordström, K., Boyde, A., Howell, P. G. T., Kelly, S., Vennström, B., & Williams, G. R. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0157 · Cited by 125
Alkaline Phosphatase Isoenzyme Patterns in Hyperthyroidism
COOPER, D. S., KAPLAN, M. M., RIDGWAY, E. C., MALOOF, F., & DANIELS, G. H. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-90-2-164 · Cited by 95
Franklyn, J., Betteridge, J., Holder, R., Daykin, J., Lilley, J., & Sheppard, M. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02572.x · Cited by 84 · cited 1×
“therapy [54, 56, 59–66].”
Approach to the Patient with Subclinical Hyperthyroidism
Cooper, D. S. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2472 · Cited by 83
Hip fractures and the thyroid: a case‐control study
Wejda, B., Hintze, G., Katschinski, B., Olbricht, T., & Benker, G. (1995) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1995.tb01172.x · Cited by 83
Steatorrhea in Thyrotoxicosis: Relation to Hypermotility and Excessive Dietary Fat
THOMAS, F. B., CALDWELL, J. H., & GREENBERGER, N. J. (1973) · Annals of Internal Medicine · doi:10.7326/0003-4819-78-5-669 · Cited by 77 · cited 1×
“Support for these finding was reported in a more recent cross-sectional study (𝑛 = 6722), which estimated a 31% higher fracture risk (forearm, hip, and vertebral) in patients with TSH <0.10mU/L compared to TSH 1.0–1.49mU/L [44].”
ResultInfluentialGÜRLEK, A., & GEDIK, O. (1999) · Thyroid · doi:10.1089/thy.1999.9.539 · Cited by 72 · cited 1×
“Similarly, the majority of studies have revealed normal serum markers of bone turnover, with the exception of the aforementioned studies, which noted significant increase in bone resorption markers in both pre- and postmenopausal women [14, 80, 82, 86, 87].”
ResultTauchmanovà, L., Nuzzo, V., Del Puente, A., Fonderico, F., Esposito-Del Puente, A., Padulla, S., Rossi, A., Bifulco, G., Lupoli, G., & Lombardi, G. (2004) · Maturitas · doi:10.1016/j.maturitas.2004.02.017 · Cited by 66
Changes in Body Composition in Women Following Treatment of Overt and Subclinical Hyperthyroidism
Greenlund, L. J. S., Nair, K. S., & Brennan, M. D. (2008) · Endocrine Practice · doi:10.4158/ep.14.8.973 · Cited by 56 · cited 2×
“Studies in this subset of patients with subclinical hyperthyroidism have revealed a strong association with improvement in BMD within as little as 6 months of reaching euthyroidism [64, 90– 92].”
BackgroundLangdahl, B. L., Loft, A. G. R., Eriksen, E. F., Mosekilde, L., & Charles, P. (1996) · European Journal of Endocrinology · doi:10.1530/eje.0.1340702 · Cited by 42 · cited 2×
“6 years of euthyroid state after successful antithyroid therapy [40, 55, 65, 69].”
BackgroundBuscemi, S., Verga, S., Cottone, S., Andronico, G., D’Orio, L., Mannino, V., Panzavecchia, D., Vitale, F., & Cerasola, G. (2007) · Journal of Endocrinological Investigation · doi:10.1007/bf03347430 · Cited by 35 · cited 1×
“Studies in this subset of patients with subclinical hyperthyroidism have revealed a strong association with improvement in BMD within as little as 6 months of reaching euthyroidism [64, 90– 92].”
BackgroundBone Turnover in Overt and Subclinical Hyperthyroidism Due to Autonomous Thyroid Adenoma
De Menis, E., Da Rin, G., Roiter, I., Legovini, P., Foscolo, G., & Conte, N. (2008) · Hormone Research · doi:10.1159/000182315 · Cited by 30
Ugur‐Altun, B., Altun, A., Arikan, E., Guldiken, S., & Tugrul, A. (2003) · Endocrine Research · doi:10.1081/erc-120026945 · Cited by 22
Rosario, P. W. (2013) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302013000200008 · Cited by 19
Cited by
Bodai, B. I., & Tuso, P. (2015) · The Permanente Journal · doi:10.7812/tpp/14-241 · Cited by 397
Abrahamsen, B., Jørgensen, H. L., Laulund, A. S., Nybo, M., Brix, T. H., & Hegedüs, L. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2244 · Cited by 112
“While the effects on bone turnover and bonemineral density are well established, uncertainty still surrounds the magnitude, dose dependency and reversibility((8)) of the effect on the long‐ term risk of osteoporotic fractures in the population as a whole and in particular fracture risk in men and in younger women.”
BackgroundDiagnosis and management of treatment-refractory hypothyroidism: an expert consensus report
Centanni, M., Benvenga, S., & Sachmechi, I. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0706-y · Cited by 113
“The first-line treatment of hypothyroidism dictates that thyroxine dosing be carefully monitored and adjusted as necessary to prevent ongoing bone loss [100].”
BackgroundFitzgerald, S. P., Bean, N. G., Falhammar, H., & Tuke, J. (2020) · Thyroid® · doi:10.1089/thy.2019.0535 · Cited by 86
van Rijn, L. E., Pop, V. J., & Williams, G. R. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0769 · Cited by 50
Metadata
- Authors
- Gorka, J., Taylor-Gjevre, R. M., & Arnason, T.
- Venue
- International Journal of Endocrinology
- Publisher
- Wiley
- Published
- 2013
- Volume
- 2013
- Pages
- 1-11
- ISSN
- 1687-8337 (ISSN-L)
- 1687-8345
- OpenAlex
- W2150905436
- Cited by
- 78
- References
- 40
- FWCI
- 5.42
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.